Company Focus
Moderna
Latest Moderna News
Biotechnology
US biotech Moderna said the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 mRNA vaccine, Spikevax, targeting the SARS-CoV-2 XFG variant, for adults and children aged six months and above. 28 August 2026
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company based in South San Francisco, California. The company operates as an R&D organization focused on immune-mediated diseases, with clinical trials conducted through external sites in the U.S. and internationally.
Latest News & Features of interest to Moderna
Biotechnology
US biotech Moderna said the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 mRNA vaccine, Spikevax, targeting the SARS-CoV-2 XFG variant, for adults and children aged six months and above. 28 August 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved Roivant subsidiary Priovant’s Lisraya (brepocitinib) 30mg for the treatment of adults with dermatomyositis (DM). Lisraya is a pill taken once daily. 28 August 2026
Biotechnology
ProFound Therapeutics, a Flagship Pioneering company based in Cambridge, Massachusetts, has received an investment commitment of up to $35 million from the Gates Foundation, including an initial $20 million payment, to support drug target and biomarker discovery for preeclampsia and eclampsia. 28 August 2026
Biotechnology
US cardiovascular biotech Cytokinetics has presented full results from ACACIA-HCM, the pivotal Phase III trial of Myqorzo (aficamten) in symptomatic non-obstructive HCM (nHCM), in the Hot Line 1 session at ESC Congress 2026 in Munich. Results were simultaneously published in The New England Journal of Medicine. 28 August 2026
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Biotechnology
US pharma major Pfizer and German biotech firm BioNTech have secured US Food and Drug Administration (FDA) clearance for the 2026-2027 formula of their COVID-19 vaccine Comirnaty (COVID-19 vaccine, mRNA), reworked to target the XFG variant. Shipping began immediately after the August 27 approval. 28 August 2026
Biotechnology
otech Rectify Pharmaceuticals today announced the presentation of the discovery of RTY-406, the company’s clinical candidate, an oral, ABCB4 /BSEP dual-targeted PFM at the American Chemical Society Fall 2026 Meeting held August 22-27, 2026 in Chicago, USA.
2026 27 August 2026
Pharmaceutical
French clinical-stage biotech Osivax and South Korean biopharmaceutical company GC Biopharma have entered a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine. 27 August 2026
Biotechnology
Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated statistically-significant and clinically-meaningful improvements across both co-primary and all key secondary endpoints at week 24, which were sustained through week 52 in both doses tested. 27 August 2026
Pharmaceutical
In February, the US Food and Drug Administration (FDA) issued draft guidance describing how developers of individualized therapies for ultra-rare genetic conditions can establish effectiveness when a randomized controlled trial is not feasible. 27 August 2026
Latest In Brief for Moderna
Biotechnology
US pharma major AbbVie is nearing an all-cash deal to acquire clinical-stage biotech Apogee Therapeutics for roughly $10.9 billion. 20 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze